var data={"title":"Phenylephrine (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Phenylephrine (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/390315?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=phenylephrine-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Phenylephrine (systemic): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=phenylephrine-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Phenylephrine (systemic): Pediatric drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504748\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician (injection): </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Physicians should completely familiarize themselves with the complete contents of this monograph before prescribing phenylephrine injection.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504766\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Little Colds Decongestant [OTC];</li>\n      <li>Medi-Phenyl [OTC] [DSC];</li>\n      <li>Nasal Decongestant PE Max St [OTC];</li>\n      <li>Nasal Decongestant [OTC];</li>\n      <li>Non-Pseudo Sinus Decongestant [OTC];</li>\n      <li>Sudafed PE Childrens [OTC];</li>\n      <li>Sudafed PE Congestion [OTC];</li>\n      <li>Sudafed PE Maximum Strength [OTC] [DSC];</li>\n      <li>Sudogest PE [OTC];</li>\n      <li>Vazculep</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9508672\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Alpha-Adrenergic Agonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504918\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypotension/shock:</b> <b>Note:</b> The Society of Critical Care Medicine (SCCM) does <b>not</b> recommend phenylephrine for septic shock <i>except</i> in the following circumstances: When norepinephrine (preferred first-line agent) is associated with serious arrhythmias, when cardiac output is known to be high and blood pressure persistently low, or when the combination of inotrope/vasopressor and low-dose vasopressin failed to achieve target mean arterial pressure and phenylephrine is used as salvage therapy (Rhodes 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV bolus: 100 to 500 mcg/dose every 10 to 15 minutes as needed (initial dose should not exceed 500 mcg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV infusion: Initial dose: 100 to 180 mcg/minute, <b>or alternatively</b>, 0.5 mcg/kg/minute; titrate to desired response. Dosing ranges between 0.4 to 9.1 mcg/kg/minute have been reported when treating septic shock (Gregory 1991).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>ACLS guideline recommendations (to treat severe hypotension [eg, systolic blood pressure &lt;70 mm Hg] and low total peripheral resistance): Cardiogenic shock (off label dose): 0.1 to 10 mcg/kg/minute (AHA [van Diepen 2017]).</i> Initial dose: 0.5 to 2 mcg/kg/minute; titrate to effect (AHA [Peberdy 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cardiogenic shock (off-label dose):</i> <b>Note</b><b>:</b> For initial vasoactive management of cardiogenic shock due to aortic stenosis, mitral stenosis, or dynamic left ventricular outflow tract (LVOT) obstruction:0.1 to 10 mcg/kg/minute (AHA [van Diepen 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypotension during anesthesia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV bolus: 40 to 100 mcg/dose every 1 to 2 minutes as needed (total dose should not exceed 200 mcg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV infusion: Initial dose: 10 to 35 mcg/minute adjusted according to blood pressure goal (not to exceed 200 mcg/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nasal congestion: </b> <i>Oral:</i> OTC labeling: 10 mg every 4 hours as needed for &le;7 days (maximum: 60 mg/24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Priapism (ischemic) (off-label use): </b>Intracavernous (off-label route): 100 to 500 mcg every 3 to 5 minutes (using a concentration of 100 to 500 mcg/mL) over the course of ~1 hour; lower concentrations in smaller volumes should be used in patients with severe cardiovascular disease (AUA [Montague 2003]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504917\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=phenylephrine-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Phenylephrine (systemic): Pediatric drug information \t&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypotension/shock</b>: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV bolus:</i> 5 to 20 mcg/kg/dose every 10 to 15 minutes as needed (AAP 1998; Shaddy 1989); initial dose should not exceed 500 mcg; maximum dose: 1,000 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV infusion:</i> Usual initial dose: 0.1 to 0.5 mcg/kg/minute; titrate to desired response (Di Gennaro 2010; Stewart 2002; Wessel 2001); in cases of shock or intraoperative hypotension, doses up to 2 mcg/kg/minute have been reported (Di Gennaro 2010; Kliegman 2011; Shaddy 1989; Stewart 2002) and for management of infundibular spasm (Tet Spell), even higher doses up to 5 mcg/kg/minute may be required (AAP 1998; Shaddy 1989)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nasal congestion: </b> <i>Oral:</i> OTC labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">4 to &lt;6 years: 2.5 mg every 4 hours as needed for &le;7 days (maximum: 15 mg/24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">6 to &lt;12 years: 5 mg every 4 hours as needed for &le;7 days (maximum: 30 mg/24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;12 years: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504919\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505013\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Liquid, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Little Colds Decongestant: 2.5 mg/mL (30 mL) [alcohol free, dye free, saccharin free; contains sodium benzoate; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (1 mL, 5 mL [DSC], 10 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vazculep: 10 mg/mL (1 mL, 5 mL, 10 mL) [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/250 mL in Dextrose 5% (250 mL); 100 mg /250 mL in NaCl 0.9% (250 mL); 20 mg/250 mL in Dextrose 5% (250 mL); 20 mg/250 mL in NaCl 0.9% (250 mL); 25 mg/250 mL in NaCl 0.9% (250 mL); 40 mg/250 mL in NaCl 0.9% (250 mL); 40 mg/500 mL in NaCl 0.9% (500 mL); 50 mg/250 mL in NaCl 0.9% (250 mL); 50 mg/500 mL in Dextrose 5% (500 mL); 80 mg/250 mL in NaCl 0.9% (250 mL); 80 mg/500 mL in NaCl 0.9% (500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sudafed PE Childrens: 2.5 mg/5 mL (118 mL) [alcohol free, sugar free; contains edetate disodium, fd&amp;c red #40, sodium benzoate; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.4 mg/10 mL in NaCl 0.9% (10 mL); 0.5 mg/5 mL in NaCl 0.9% (5 mL); 0.8 mg/10 mL in NaCl 0.9% (10 mL); 1 mg/10 mL (10 mL); 1 mg/10 mL in NaCl 0.9% (10 mL); 100 mcg/10 mL in NaCl 0.9% (10 mL); 20 mg/50 mL in NaCl 0.9% (50 mL); 200 mcg/5 mL in NaCl 0.9% (5 mL); 5 mg/50 mL in NaCl 0.9% (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Medi-Phenyl: 5 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nasal Decongestant: 10 mg [contains fd&amp;c blue #2 (indigotine), fd&amp;c red #40, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nasal Decongestant PE Max St: 10 mg [pseudoephedrine free; contains fd&amp;c red #40 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Non-Pseudo Sinus Decongestant: 10 mg [contains fd&amp;c red #40 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sudafed PE Congestion: 10 mg [contains fd&amp;c red #40 aluminum lake, fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sudafed PE Maximum Strength: 10 mg [DSC] [contains fd&amp;c red #40 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sudogest PE: 10 mg [contains fd&amp;c red #40]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504775\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504945\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hypotension/shock:</i> May be administered as an intermittent IV bolus over 20 to 30 seconds or via continuous infusion (after diluting). When administering as a continuous infusion, central line administration is preferred. IV infusions require an infusion pump.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hypotension during anesthesia:</i> Administer as an IV bolus over 20 to 30 seconds.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Initiate phentolamine (or alternative antidote). Apply dry warm compresses (Hurst 2004; Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Phentolamine:</i> Dilute 5 to 10 mg in 10 to 20 mL NS and administer into extravasation site as soon as possible after extravasation; may readminister if patient remains symptomatic (Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternative to phentolamine:</i> Nitroglycerin topical 2% ointment (based on limited data):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Adults:</i> Apply a 1-inch strip to the site of ischemia; may repeat every 8 hours as necessary (Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Pediatrics:</i> Apply 4 mm/kg as a thin ribbon to the site of ischemia; may repeat after 8 hours if needed (Wong 1992) <b>or</b> apply a 1-inch strip to the site of ischemia; may repeat every 8 hours as necessary (Denkler 1989; Reynolds 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14473053\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 10 mg in 500 mL (concentration: 20 <b>mcg</b>/mL) of D<sub>5</sub>W or NS, 50 mg in 500 mL (concentration: 100 <b>mcg</b>/mL) of NS, <b>or</b> 100 mg in 500 mL (concentration: 200 <b>mcg</b>/mL) of NS</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Other institutions may use concentrations of 40 <b>mcg</b>/mL <b>or</b> 160 <b>mcg</b>/mL; however, stability information is not available for these concentrations. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14473054\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 20 <b>mcg</b>/mL, 40 <b>mcg</b>/mL, or 60 <b>mcg</b>/mL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504776\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypotension/shock:</b> Treatment of hypotension, vascular failure in shock. <b>Note:</b> Not recommended for routine use in the treatment of septic shock; use should be limited until more evidence demonstrating positive clinical outcomes becomes available (Rhodes 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Guideline recommendations: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>\n        <i>Cardiogenic shock:</i></b> The 2017 American Heart Association (AHA) scientific statement for the Contemporary Management of Cardiogenic Shock recommends phenylephrine, if needed, be considered for initial vasoactive management of cardiogenic shock due to aortic stenosis, mitral stenosis, or dynamic left ventricular outflow tract (LVOT) obstruction (AHA [van Diepen 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypotension during anesthesia:</b> As a vasoconstrictor in regional analgesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nasal congestion:</b> As a decongestant [OTC]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27749511\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Hypotension in patients with obstructive hypertrophic cardiomyopathy; Priapism (ischemic)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504764\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Sudafed PE may be confused with Sudafed</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Vazculep may be confused with Bloxiverz (neostigmine) due to similar packaging</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (IV formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504784\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Injection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Cardiac arrhythmia (rare), exacerbation of angina, hypertension, hypertensive crisis, ischemia, localized blanching, low cardiac output, peripheral vasoconstriction (severe), reflex bradycardia, visceral vasoconstriction (severe), worsening of heart failure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Anxiety, dizziness, excitability, headache, insomnia, nervousness, paresthesia, precordial pain (or discomfort), restlessness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Pallor, piloerection, pruritus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Metabolic acidosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Epigastric pain, gastric irritation, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Decreased renal blood flow, decreased urine output</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction (including skin rash, urticaria, leukopenia, agranulocytosis, thrombocytopenia)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Neck pain, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Blurred vision</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Dyspnea, respiratory distress</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Oral:</b> Central nervous system: Anxiety, dizziness, excitability, headache, insomnia, nervousness, restlessness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504781\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to phenylephrine or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Severe hypertension; ventricular tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vazculep: There are no contraindications listed in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OTC labeling (Oral): When used for self-medication: Use with or within 14 days of MAO inhibitor therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504782\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: Intravenous use of phenylephrine may cause severe bradycardia (likely baroreflex mediated) and reduced cardiac output due to an increase in cardiac afterload especially in patients with preexisting cardiac dysfunction (Goertz 1993; Yamazaki 1982). May also precipitate angina in patients with severe coronary artery disease and increase pulmonary arterial pressure. Use with caution in patients with preexisting bradycardia, partial heart block, myocardial disease, or severe coronary artery disease. Avoid or use with extreme caution in patients with heart failure or cardiogenic shock; increased systemic vascular resistance may significantly reduce cardiac output. Avoid use in patients with hypertension (contraindicated in severe hypertension); monitor blood pressure closely and adjust infusion rate. May also cause excessive peripheral and visceral vasoconstriction and ischemia to vital organs, particularly in patients with extensive peripheral vascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: IV administration: Vesicant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acidosis: Acidosis may reduce the efficacy of phenylephrine; correct acidosis prior to or during use of phenylephrine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autonomic dysfunction: Patients with autonomic dysfunction (eg, spinal cord injury) may exhibit an exaggerated increase in blood pressure response to phenylephrine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Monoamine oxidase inhibitors (MAO-I): Use with extreme caution in patients taking MAO inhibitors; hypertension may result from concurrent use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral: When used for self-medication (OTC), use with caution in patients with asthma, bowel obstruction/narrowing, hyperthyroidism, diabetes mellitus, cardiovascular disease, ischemic heart disease, hypertension, increased intraocular pressure, prostatic hyperplasia or in the elderly. Notify healthcare provider if symptoms do not improve within 7 days or are accompanied by fever. Discontinue and contact health care provider if nervousness, dizziness, or sleeplessness occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfites: Some products contain sulfites which may cause allergic reactions in susceptible individuals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: When used intravenously in patients who are hypotensive, assure adequate circulatory volume to minimize need for vasoconstrictors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Trained personnel: <b> [US Boxed Warning]: Intravenous preparations should be administered by adequately trained individuals familiar with its use.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299870\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504824\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9900&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen: May increase the serum concentration of Phenylephrine (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloroprocaine: May enhance the hypertensive effect of Phenylephrine (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: May diminish the therapeutic effect of Phenylephrine (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.<b> Exceptions: </b>Ergoloid Mesylates; Nicergoline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Systemic). Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of phenylephrine.  Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioflupane I 123: Phenylephrine (Systemic) may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to linezolid specific monographs for details.<b> Exceptions: </b>Linezolid; Tedizolid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propacetamol: May increase the serum concentration of Phenylephrine (Systemic). Management: Monitor patients closely for increased side effects of phenylephrine if propacetamol is used concomitantly. Patients with underlying blood pressure issues or arrhythmias may need closer monitoring and may warrant consideration of alternative therapies.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the vasopressor effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504777\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504778\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Phenylephrine crosses the placenta at term. Maternal use of phenylephrine during the first trimester of pregnancy is not strongly associated with an increased risk of fetal malformations; maternal dose and duration of therapy were not reported in available publications. Phenylephrine is available over-the-counter (OTC) for the symptomatic relief of nasal congestion. Decongestants are not the preferred agents for the treatment of rhinitis during pregnancy. Oral phenylephrine should be avoided during the first trimester of pregnancy; short-term use (&lt;3 days) of intranasal phenylephrine may be beneficial to some patients although its safety during pregnancy has not been studied. Phenylephrine injection is used at delivery for the prevention and/or treatment of maternal hypotension associated with spinal anesthesia in women undergoing cesarean section. Phenylephrine may be associated with a more favorable fetal acid base status than ephedrine; however, overall fetal outcomes appear to be similar. Nausea or vomiting may be less with phenylephrine than ephedrine but is also dependent upon blood pressure control. Phenylephrine may be preferred in the absence of maternal bradycardia. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11393286\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if phenylephrine is present in breast milk. The manufacturer recommends that caution be exercised when administering phenylephrine to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504944\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain phenylalanine and/or sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504948\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure (or mean arterial pressure), heart rate; cardiac output (as appropriate), intravascular volume status, pulmonary capillary wedge pressure (as appropriate); monitor infusion site closely</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Consult individual institutional policies and procedures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504869\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Potent, direct-acting alpha-adrenergic agonist with virtually no beta-adrenergic activity; produces systemic arterial vasoconstriction. Such increases in systemic vascular resistance result in dose dependent increases in systolic and diastolic blood pressure and reductions in heart rate and cardiac output especially in patients with heart failure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504889\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Blood pressure increase/vasoconstriction: IM, SubQ: 10 to 15 minutes; IV: Immediate</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nasal decongestant: Oral: 15 to 30 minutes (Kollar 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Blood pressure increase/vasoconstriction: IM: 1 to 2 hours; IV: ~15 to 20 minutes; SubQ: 50 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nasal decongestant: Oral: &le;4 hours (Kollar 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Erratic and incomplete (Kanfer 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Initial: 26 to 61 L; V<sub>dss</sub>: 184 to 543 L (mean: 340 L) (Hengstmann 1982)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via oxidative deamination (Oral: 24%; IV: 50%); Undergoes sulfation (Oral [mostly within gut wall]: 46%; IV: 8%) and some glucuronidation; forms inactive metabolites (Kanfer 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: &le;38% (Hengstmann 1982; Kanfer 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Alpha phase: ~5 minutes; Terminal phase: 2 to 3 hours (Hengstmann 1982; Kanfer 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Oral: 0.75 to 2 hours (Kanfer 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (mostly as inactive metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322400\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Little Colds Decongestant Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg/mL (30 mL): $3.89</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Phenylephrine HCl-Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20MG/250ML 5% (250 mL): $23.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50MG/500ML 5% (500 mL): $48.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Phenylephrine HCl-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10MG/250ML 0.9% (250 mL): $16.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20MG/250ML 0.9% (250 mL): $23.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25MG/250ML 0.9% (250 mL): $28.67</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/500 mL 0.9% (500 mL): $41.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40MG/250ML 0.9% (250 mL): $37.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50MG/250ML 0.9% (250 mL): $44.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg/500 mL 0.9% (500 mL): $69.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80MG/250ML 0.9% (250 mL): $69.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100MG/250ML 0.9% (250 mL): $82.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Sudafed PE Childrens Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg/5 mL (118 mL): $5.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Vazculep Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (1 mL): $5.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Phenylephrine HCl-NaCl (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4MG/10ML 0.9% (10 mL): $5.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5MG/5ML 0.9% (5 mL): $5.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.8MG/10ML 0.9% (10 mL): $5.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1MG/10ML 0.9% (10 mL): $5.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100MCG/10ML 0.9% (10 mL): $6.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200MCG/5ML 0.9% (5 mL): $4.78</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Phenylephrine HCl-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1MG/10ML 0.9% (10 mL): $5.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/50 mL 0.9% (50 mL): $14.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/50 mL 0.9% (50 mL): $24.73</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sudafed PE Congestion Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (18): $6.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sudogest PE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (18): $3.79</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961999\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>AK-Dilate (PE);</li>\n      <li>Albalon Relief (AU, NZ);</li>\n      <li>Davinefrina (PT);</li>\n      <li>Denason (BR);</li>\n      <li>Drosyn (IN);</li>\n      <li>Efrin-10 (IL);</li>\n      <li>Ethifrin (PK);</li>\n      <li>Fadalefrina (AR, UY);</li>\n      <li>Fenilefrina (BR);</li>\n      <li>Fenylefrinhydroklorid (NO);</li>\n      <li>Humex Nosni (CZ);</li>\n      <li>Humoxal (FR);</li>\n      <li>Irifrin (RU);</li>\n      <li>Isonefrine (PK);</li>\n      <li>Isopto Frin (AU, EC);</li>\n      <li>Metaoxedrin (DK, NO);</li>\n      <li>Midfrin (KR);</li>\n      <li>Midriafen (CO);</li>\n      <li>Minims Phenylephrine HCL 10% (ZA);</li>\n      <li>Minims Phenylephrine Hydrochloride (GB, IE);</li>\n      <li>Mydfrin (AE, BG, BH, CN, CY, EG, HK, IQ, IR, JO, KW, LB, LY, MY, OM, PH, PY, QA, SA, SG, SY, UY, YE);</li>\n      <li>Nasalate Nose Cream (AU);</li>\n      <li>Nasenspray (CH);</li>\n      <li>Nefrisol (LK);</li>\n      <li>Neo-Sinefrina (PT);</li>\n      <li>Neo-Synephrine (IT);</li>\n      <li>Neo-Synephrine Ophthalmic (BE, DE, PH);</li>\n      <li>Neosinicin (TW);</li>\n      <li>Neosynephrin-POS (CZ, DE);</li>\n      <li>Neosynephrine Faure 10% (FR);</li>\n      <li>Oftan-Metaoksedrin (FI);</li>\n      <li>OQ-Dilat (CO);</li>\n      <li>Prefrin (AE, AR, AU, BH, CY, EC, EG, IL, IQ, IR, JO, KW, LB, LY, NZ, OM, QA, SA, SY, YE, ZA);</li>\n      <li>Qura Nasal (AR);</li>\n      <li>Visadron (AT, BE, DE, NL, PT);</li>\n      <li>We Li Ang (CL)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beale RJ, Hollenberg SM, Vincent JL, et al, &ldquo;Vasopressor and Inotropic Support in Septic Shock: An Evidence Based Review,&rdquo; <i>Crit Care Med</i>, 2004, 32(11 Suppl):455-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/15542956/pubmed\" target=\"_blank\" id=\"15542956\">15542956</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bonfiglio MF, Dasta JF, Gregory JS, et al, &ldquo;High-Dose Phenylephrine Infusion in the Hemodynamic Support of Septic Shock,&rdquo; <i>DICP</i>, 1990, 24(10):936-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/2244407/pubmed\" target=\"_blank\" id=\"2244407\">2244407</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Committee on Drugs, 1996 to 1997, Liaison Representatives, and AAP Section Liaisons. Drugs for pediatric emergencies. <i>Pediatrics</i>. 1998;101(1):E13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/9734990/pubmed\" target=\"_blank\" id=\"9734990\">9734990</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Denkler KA and Cohen BE, &ldquo;Reversal of Dopamine Extravasation Injury With Topical Nitroglycerin Ointment,&rdquo; <i>Plast Reconstr Surg</i>, 1989, 84(5):811-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/2510208/pubmed\" target=\"_blank\" id=\"2510208\">2510208</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Di Gennaro JL, Mack CD, Malakouti A, et al. Use and effect of vasopressors after pediatric traumatic brain injury. <i>Dev Neurosci</i>. 2010;32(5-6):420-430. doi: 10.1159/000322083.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/21124016/pubmed\" target=\"_blank\" id=\"21124016\">21124016</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1856926\"></a>Dittrich A, Albrecht K, Bar-Moshe O, Vandendris M. Treatment of pharmacological priapism with phenylephrine. <i>J Urol</i>. 1991;146(2):323-324.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/1856926/pubmed\" target=\"_blank\" id=\"1856926\">1856926</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flancbaum L, Dick M, Dasta J, et al, &ldquo;A Dose-Response Study of Phenylephrine in Critically Ill, Septic Surgical Patients,&rdquo; <i>Eur J Clin Pharmacol</i>, 1997, 51(6):461-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/9112060/pubmed\" target=\"_blank\" id=\"9112060\">9112060</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goertz AW, Lindner KH, Seefelder C, et al, &ldquo;Effect of Phenylephrine Bolus Administration on Global Left Ventricular Function in Patients With Coronary Artery Disease and Patients With Valvular Aortic Stenosis,&rdquo; <i>Anesthesiology</i>, 1993, 78(5):834-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/8489054/pubmed\" target=\"_blank\" id=\"8489054\">8489054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gregory JS, Bonfiglio MF, Dasta JF, et al, &ldquo;Experience With Phenylephrine as a Component of the Pharmacologic Support of Septic Shock,&rdquo; <i>Crit Care Med</i>, 1991, 19(11):1395-400.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/1935160/pubmed\" target=\"_blank\" id=\"1935160\">1935160</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gupta VD, &ldquo;Chemical Stability of Phenylephrine Hydrochloride After Reconstitution in 0.9% Sodium Chloride Injection for Infusion,&rdquo; <i>Int J Pharmaceut Compound</i>, 2004, 8(2):153-5</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hengstmann JH and Goronzy J, &ldquo;Pharmacokinetics of 3H-Phenylephrine in Man,&rdquo; <i>Eur J Clin Pharmacol</i>, 1982, 21(4):335-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/7056280/pubmed\" target=\"_blank\" id=\"7056280\">7056280</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25695573\"></a>Hensley N, Dietrich J, Nyhan D, Mitter N, Yee MS, Brady M. Hypertrophic cardiomyopathy: a review. <i>Anesth Analg</i>. 2015;120(3):554-569.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/25695573/pubmed\" target=\"_blank\" id=\"25695573\">25695573</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hollenberg SM, Ahrens TS, Annane D, et al, &ldquo;Practice Parameters for Hemodynamic Support of Sepsis in Adult Patients: 2004 Update,&rdquo; <i>Crit Care Med</i>, 2004, 32(9):1928-48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/15343024/pubmed\" target=\"_blank\" id=\"15343024\">15343024</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S and McMillan M, &ldquo;Innovative Solutions in Critical Care Units: Extravasation Guidelines,&rdquo; <i>Dimens Crit Care Nurs</i>, 2004, 23(3):125-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kanfer I, Dowse R, and Vuma V, &ldquo;Pharmacokinetics of Oral Decongestants,&rdquo; <i>Pharmacotherapy</i>, 1993, 13(6 Pt 2):116-28; discussion 143-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/7507589/pubmed\" target=\"_blank\" id=\"7507589\">7507589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kiser TH, Oldland AR, Fish DN. Stability of phenylephrine hydrochloride injection in polypropylene syringes. <i>Am J Health-Syst Pharm</i>. 2007;64(10):1092-1095.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/17494910/pubmed\" target=\"_blank\" id=\"17494910\">17494910</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kollar C, Schneider H, Waksman J, et al, &ldquo;Meta-Analysis of the Efficacy of Single Dose of Phenylephrine 10 Mg Compared With Placebo in Adults With Acute Nasal Congestion Due to the Common Cold,&rdquo; <i>Clin Ther</i>, 2007, 29(6):1057-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/17692721/pubmed\" target=\"_blank\" id=\"17692721\">17692721</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montague DK, Jarow J, Broderick GA, et al; Members of the Erectile Dysfunction Guideline Update Panel; Americal Urological Association. American Urological Association guideline on the management of priapism. <i>J Urol</i>. 2003;170(4 Pt 1):1318-1324.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/14501756/pubmed\" target=\"_blank\" id=\"14501756\">14501756</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16942536\"></a>Munarriz R, Wen CC, McAuley I, Goldstein I, Traish A, Kim N. Management of ischemic priapism with high-dose intracavernosal phenylephrine: from bench to bedside. <i>J Sex Med</i>. 2006;3(5):918-22. Erratum in: <i>J Sex Med</i>. 2006;3(5):938.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/16942536/pubmed\" target=\"_blank\" id=\"16942536\">16942536</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care [published corrections appear in <i>Circulation</i>. 2013;128(25):e480; <i>Circulation</i>. 2011;123(6):e236]. <i>Circulation</i>. 2010;122(18)(suppl 3):S729-S767.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/20956224/pubmed\" target=\"_blank\" id=\"20956224\">20956224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15044643\"></a>Nishimura RA, Holmes DR Jr. Clinical practice. Hypertrophic obstructive cardiomyopathy. <i>N Engl J Med</i>. 2004;350(13):1320-1327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/15044643/pubmed\" target=\"_blank\" id=\"15044643\">15044643</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peberdy MA, Callaway CW, Neumar RW, et al, &ldquo;Part 9: Post Cardiac Arrest Care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):768-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/20956225/pubmed\" target=\"_blank\" id=\"20956225\">20956225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phenylephrine injection (prescribing information). Irvine, CA: Teva Parenteral Medicines; October 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo; <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/22058104/pubmed\" target=\"_blank\" id=\"22058104\">22058104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24420913\"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/24420913/pubmed\" target=\"_blank\" id=\"24420913\">24420913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28098591\"></a>Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. <i>Crit Care Med</i>. 2017;45(3):486-552.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/28098591/pubmed\" target=\"_blank\" id=\"28098591\">28098591</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shaddy RE, Viney J, Judd VE, McGough EC. Continuous intravenous phenylephrine infusion for treatment of hypoxemic spells in tetralogy of Fallot. <i>J Pediatr</i>. 1989;114(3):468-470.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/2921691/pubmed\" target=\"_blank\" id=\"2921691\">2921691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stewart JM, Munoz J, Weldon A. Clinical and physiological effects of an acute alpha-1 adrenergic agonist and a beta-1 adrenergic antagonist in chronic orthostatic intolerance. <i>Circulation</i>. 2002;106(23):2946-2954.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/12460877/pubmed\" target=\"_blank\" id=\"12460877\">12460877</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sudogest (phenylephrine) [prescribing information]. Livonia, MI: Major Pharmaceuticals; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28923988\"></a>van Diepen S, Katz JN, Albert NM, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; Mission: Lifeline. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. <i>Circulation</i>. 2017;136(16):e232-e268. doi:10.1161/CIR.0000000000000525.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/28923988/pubmed\" target=\"_blank\" id=\"28923988\">28923988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vazculep (phenylephrine hydrochloride) [prescribing information]. Chesterfield, MO: Avadel Legacy Pharmaceuticals; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Waxman MB, Bonet JF, Finley JP, et al. Effects of respiration and posture on paroxysmal supraventricular tachycardia. <i>Circulation</i>. 1980;62(5):1011-1020.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/7418151/pubmed\" target=\"_blank\" id=\"7418151\">7418151</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber CR and Gupta VD, &ldquo;Stability of Phenylephrine Hydrochloride in Intravenous Solutions,&rdquo; <i>J Hosp Pharm</i>, 1970, 28:200-8.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wessel DL. Managing low cardiac output syndrome after congenital heart surgery. <i>Crit Care Med</i>. 2001;29(10 suppl):S220-S230.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/11593065/pubmed\" target=\"_blank\" id=\"11593065\">11593065</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1447671\"></a>Wong AF, McCulloch LM, and Sola A, &ldquo;Treatment of Peripheral Tissue Ischemia With Topical Nitroglycerin Ointment in Neonates,&rdquo; <i>J Pediatr</i>, 1992, 121(6):980-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/1447671/pubmed\" target=\"_blank\" id=\"1447671\">1447671</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yamazaki T, Shimada Y, Taenaka N, et al, &ldquo;Circulatory Responses to Afterloading with Phenylephrine in Hyperdynamic Sepsis,&rdquo; <i>Crit Care Med</i>, 1982, 10(7):432-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-drug-information/abstract-text/7083867/pubmed\" target=\"_blank\" id=\"7083867\">7083867</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9900 Version 181.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F9504748\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9504766\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F9508672\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F9504918\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F9504917\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F9504919\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9505013\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F9504775\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9504945\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F14473053\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14473054\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F9504776\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F27749511\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9504764\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9504784\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9504781\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9504782\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299870\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9504824\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F9504777\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9504778\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F11393286\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F9504944\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F9504948\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9504869\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F9504889\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322400\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961999\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9900|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=phenylephrine-systemic-patient-drug-information\" class=\"drug drug_patient\">Phenylephrine (systemic): Patient drug information \t</a></li><li><a href=\"topic.htm?path=phenylephrine-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Phenylephrine (systemic): Pediatric drug information \t</a></li></ul></div></div>","javascript":null}